Related Experiment Video
Updated: Aug 15, 2026
Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
Published on: June 16, 2017
Analysis of methylation pattern in multiple myeloma
Jesús San-Miguel1, Ramón García-Sanz, Ricardo López-Pérez
1Servicio de Hematología, Hospital Universitario de Salamanca, Centro de Investigación del Cáncer, Universidad de Salamanca, Salamanca, Spain. sanmigiz@usal.es
Abstract:
DNA methylation is involved in malignancy and is seen, in progression, in more than 80% of all solid tumours. Methylation is one of the main physiological processes to induce silencing of gene expression. Much work has focused on the suppressor gene p16, which acts as a negative cell cycle regulator, while its inhibition (via methylation) will have a positive effect on the cell cycle advance. The methylation status of the p16 gene was analysed in a group of 159 patients. Methylation of the p16 gene was seen in 41/98 (42%) patients with multiple myeloma and 4/5 (80%) patients with primary plasma cell leukaemias. This data favours the importance of p16 methylation on cell cycle regulation in multiple myeloma. In a proposed mechanism, methylated CpG islands attract a protein, MeCP2, which recruits a transcriptional inhibitory complex that includes histone deacetylases. The deacetylated lysine tails of the histones closely interact with DNA, resulting in a transcriptionally repressed chromatin with inhibited gene transcription, providing potential synergy between demethylating drugs and histone deacetylase inhibitors. Based on the knowledge of epigenetic mechanisms, the potential application of demethylating agents should be further investigated. Multiple myeloma remains an incurable disease, so new treatment strategies are needed to improve the outcome of patients.
Insights
DNA methylation, a key epigenetic process, silences gene expression. P16 gene methylation was observed in multiple myeloma, suggesting its role in cell cycle regulation and potential therapeutic targets.
Area of Science:
- Epigenetics and Molecular Oncology
- Cancer Biology
Background:
- DNA methylation is a critical epigenetic mechanism involved in gene silencing and cancer development.
- The p16 gene, a tumor suppressor, regulates the cell cycle and its methylation is implicated in various solid tumors.
Purpose of the Study:
- To investigate the methylation status of the p16 gene in patients with multiple myeloma and primary plasma cell leukaemias.
- To explore the role of p16 gene methylation in cell cycle regulation within the context of multiple myeloma.
Main Methods:
- Analysis of p16 gene methylation status in 159 patients.
- Comparison of methylation frequencies between multiple myeloma and primary plasma cell leukaemia cohorts.
Main Results:
- P16 gene methylation was detected in 42% of multiple myeloma patients (41/98).
- A higher frequency of p16 gene methylation (80%) was observed in primary plasma cell leukaemias (4/5).
- Findings support the significance of p16 methylation in multiple myeloma cell cycle regulation.
Conclusions:
- P16 gene methylation plays a role in the progression of multiple myeloma.
- Epigenetic mechanisms like DNA methylation offer potential therapeutic strategies, including demethylating agents and histone deacetylase inhibitors.
- Further research into epigenetic therapies is crucial for improving outcomes in multiple myeloma, an incurable disease.
